TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean MOS SF-36 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Harris hip score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean IMT change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of ineligible patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase in arterial oxygen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease in alveolar-arterial oxygen gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevention of recurrence of primary pterygium
Endpoint domain: Mortality/survival
Primary endpoint: Creatinine levels at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Creatinine clearance on postoperative days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary output on the first postoperative day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Participant satisfaction with the study
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Agreement that the dietitian took time to ask about important things
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BPI pain severity and interference scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate Ratio of activity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-body protein turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-body protein synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cannulation failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total paracetamol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success of breast conservation after preoperative chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: subjective sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: economic efficiency in improving physical function
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Brief Pain Inventory severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Pain Inventory interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's Global Impression of Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Reduction in palatal erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased consumption of added sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decreased total fat consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increased vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-perceived levels of drowsiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative levels of myoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative levels of troponin T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lactate extraction calculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum ionised calcium (iCa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma parathormone level (PTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hypercalcemia frequency
Endpoint domain: Adverse events/effects
Primary endpoint: antibody responses to p24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to VL <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with VL <50 or <40 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five times sit-to-stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Four-meter walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in diastolic functional parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in interventricular septal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of students observed drinking water during lunch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in water intake across all students
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of intervention students observed with sugar-sweetened beverages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary patency at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days not covered by effective contraceptive use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Feeling State (FS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feeling Arousal Scale (FAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Energetic Arousal (EA)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients reaching systolic BP goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients achieving 95% ETO2 at 5 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximal ETO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ETO2 at conclusion of O2 administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fALFF values in the frontal lobe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hamilton's depression scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ADL decline or nursing home placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: live birth rate per participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Improvement in IIEF-5 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Improvement in IPSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cognition improvement measured by MMSE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognition improvement measured by fluency score (ADS 6 test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Preference for axillary dissection
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: delayed recall memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance of IADLs
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postoperative distance of the bladder base to the inferior edge of the symphysis pubis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of stress incontinence
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of urge incontinence
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of recurrent cystocele
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in the appearance of striae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increased dermal elastin content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PBVC reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implementation cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Vein visibility and palpability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of IVC attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Full remission (CDAI, < 150)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meaning of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Life respect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean ferritin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: prevalence of iron deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: prevalence of neonatal anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Duration of disease control (DDC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-Improvement scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMAI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of upper lip movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dimensional changes of the upper lip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global psychological symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absence of fever and improvement of 30% or more on ACR core set variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total dose of morphine consumed during the first 24 postoperative hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: initial pain VAS means
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction and incidence of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Serum levels of GH and IGF-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Acromegaly symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of fentanyl analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of lower extremity weakness
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction rate of ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DESIGN-R score decrease
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients with a tolerable level of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean levels of cholesterol, triglycerides, and LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean levels of HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: physiological quality in seeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: viability of seeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCL-D13 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Target preoperative FBG achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of endometrial carcinoma
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of fibrocystic breast disease
Endpoint domain: Adverse events/effects
Primary endpoint: Change in plasma CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle stiffness of the gastrocnemius in a relaxed state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Median patient-reported pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venipuncture success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cell viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apoptosis induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean cardiometabolic and inflammatory marker concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean IRLS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients classified as symptom-free (IRLS = 0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of application site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from AF at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to first return to apyrexia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative malocclusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gastric ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Normal endoscopy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reduced antisaccade errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alpha-tocopherol absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of protamine administered
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of residual circulating heparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recurrent P. vivax infections
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of recurrent infections at month 12
Endpoint domain: Adverse events/effects
Primary endpoint: Median time to recurrence of P. vivax parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall five-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Mean sitting diastolic blood pressure (msDBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Control rate of blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Helkimo Index D 0 - D III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain reported in joints and movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity Score (DAS) remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sE-selectin, sL-selectin, and sPECAM-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: myocardial metabolic recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: myocardial functional recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: local-regional recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: primary failure rate
Endpoint domain: Mortality/survival
Primary endpoint: moderate to severe complications
Endpoint domain: Adverse events/effects
Primary endpoint: limits of stability reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: limits of stability maximal excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Test of Sensory Interaction of Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experience of excess skin
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Discomfort from excess skin
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Annual incidence of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: perceived hypernasality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean nasalance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to attain stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in CGHAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic and histologic evidence of mucosal healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of inflammation of pouch mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pulmonary complications (atelectasis or infiltrates)
Endpoint domain: Adverse events/effects
Primary endpoint: Early postoperative hypocalcemia prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serum prolactin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: BMI decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GI event scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: sperm count reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: NV total reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate at 12 months after a single ablation procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life (HRQOL) as measured by FACT-G
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Successful treatment rate after 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative success percentage after 7 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with fecal incontinence at age 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVD rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Script concordance test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean breast surface dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final exam scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Peak concentration (C(max)) of glibenclamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve of glibenclamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with Depo-Provera
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improved inspiratory capacity (IC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved forced expiratory volume in 1 s (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased 6-min walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost-effectiveness (incremental cost per QALY gained)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of articular subsidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cost of managing psoriatic patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Inspiratory temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sport participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Anterior knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of injections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Therapeutic success of LP therapy in patients with allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes